Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?

Author(s): M. Galuppo, E. Mazzon, S. Giacoppo, O. Bereshchenko, S. Bruscoli, C. Riccardi and P. Bramanti

Volume 15, Issue 10, 2015

Page: [990 - 993] Pages: 4

DOI: 10.2174/1566524016666151123114825

Price: $65

Abstract

Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.

Keywords: Relapsing/remitting multiple sclerosis, first diagnosis patients, Wnt/β-catenin pathway, natalizumab, interferon-beta, neurodegenerative disease.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy